Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPAR gamma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Jun Young | - |
dc.contributor.author | Bae, Hwan | - |
dc.contributor.author | Lee, Yong Jae | - |
dc.contributor.author | Il Choi, Young | - |
dc.contributor.author | Kim, Hyun-Jung | - |
dc.contributor.author | Park, Seung Bum | - |
dc.contributor.author | Suh, Se Won | - |
dc.contributor.author | Kim, Sang Wan | - |
dc.contributor.author | Han, Byung Woo | - |
dc.date.available | 2019-01-22T14:13:51Z | - |
dc.date.issued | 2018-01-08 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/1326 | - |
dc.description.abstract | Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of the nuclear receptor superfamily. It functions as a ligand-activated transcription factor and plays important roles in the regulation of adipocyte differentiation, insulin resistance, and inflammation. Here, we report the crystal structures of PPAR gamma in complex with lobeglitazone, a novel PPAR gamma agonist, and with rosiglitazone for comparison. The thiazolidinedione (TZD) moiety of lobeglitazone occupies the canonical ligand-binding pocket near the activation function-2 (AF-2) helix (i. e., helix H12) in ligand-binding domain as the TZD moiety of rosiglitazone does. However, the elongated p-methoxyphenol moiety of lobeglitazone interacts with the hydrophobic pocket near the alternate binding site of PPAR gamma. The extended interaction of lobeglitazone with the hydrophobic pocket enhances its binding affinity and could affect the cyclindependent kinase 5 (Cdk5)-mediated phosphorylation of PPAR gamma at Ser245 (in PPAR gamma 1 numbering; Ser273 in PPAR gamma 2 numbering). Lobeglitazone inhibited the phosphorylation of PPAR gamma at Ser245 in a dose-dependent manner and exhibited a better inhibitory effect on Ser245 phosphorylation than rosiglitazone did. Our study provides new structural insights into the PPAR gamma regulation by TZD drugs and could be useful for the discovery of new PPAR gamma ligands as an anti-diabetic drug, minimizing known side effects. | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.title | Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPAR gamma | - |
dc.type | Article | - |
dc.identifier.doi | 10.1038/s41598-017-18274-1 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.8, no.1 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000419441300031 | - |
dc.identifier.scopusid | 2-s2.0-85042182540 | - |
dc.citation.number | 1 | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 8 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordPlus | ACTIVATED-RECEPTOR-GAMMA | - |
dc.subject.keywordPlus | LIGAND-BINDING DOMAIN | - |
dc.subject.keywordPlus | MOLECULAR RECOGNITION | - |
dc.subject.keywordPlus | FATTY-ACIDS | - |
dc.subject.keywordPlus | NUCLEAR RECEPTORS | - |
dc.subject.keywordPlus | CRYSTAL-STRUCTURE | - |
dc.subject.keywordPlus | BARBITURIC-ACID | - |
dc.subject.keywordPlus | AGONISTS | - |
dc.subject.keywordPlus | THIAZOLIDINEDIONE | - |
dc.subject.keywordPlus | CRYSTALLOGRAPHY | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.